RadNet, Inc., (NASDAQ: RDNT) today announced that it has received FDA clearance for the third-generation release of its Quantib Prostate™ 3.0 MRI artificial intelligence (AI) software, further enhancing the offering with new and updated tools. Quantib Prostate™ software for MRI reading support was first introduced in the US, followed by a class IIb CE marking in Europe in 2021.
https://finance.yahoo.com/news/radnet-quantib-b-v-subsidiary-100000471.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.